Literature DB >> 16721023

Evolution of technology for automated peritoneal dialysis.

Claudio Ronco1, Richard Amerling, Roberto Dell'Aquila, Maria Pia Rodighiero, Pierluigi Di Loreto.   

Abstract

Automated peritoneal dialysis (APD) is important for the further penetration of PD in the dialysis marketplace. Long dwell, equilibration PD (CAPD) has limited applicability in many patients due to inadequate solute clearance or fast membrane transport characteristics. Providing large volumes of dialysate over circumscribed hours is highly labor intensive without an automated system. Early attempts at APD were crude but effective in reducing labor, which was generally provided by nursing staff. Later evolution of PD technology has been greatly accelerated by the microchip, and by miniaturization of components. Current generation machines allow individualized fill volumes, variable tidal volumes and additional daytime automated exchanges, teledialysis, memorized delivery control, and full portability. The ideal machine should not only be able to perform all treatment schedules, but it should also optimize the performance of a selected treatment strategy. Biocompatible solutions, improved osmotic agents, and sorbent technology are all adaptable to APD. The eventual evolution toward continuous flow PD will resolve many of the current problems with both CAPD and APD.

Entities:  

Mesh:

Year:  2006        PMID: 16721023     DOI: 10.1159/000093624

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  2 in total

1.  Strategies for Prevention and Treatment of Peritoneal Fibrosis: A Scientometric Study.

Authors:  Sudabeh Alatab; Iraj Najafi; Ozra Tabatabaei-Malazy; Gholamreza Pourmand; Naser Ahmadbeigi
Journal:  Int J Prev Med       Date:  2019-05-17

2.  Application of automated peritoneal dialysis in urgent-start peritoneal dialysis patients during the break-in period.

Authors:  Shengmao Liu; Xiaohua Zhuang; Min Zhang; Yanfeng Wu; Min Liu; Sibo Guan; Shujun Liu; Lining Miao; Wenpeng Cui
Journal:  Int Urol Nephrol       Date:  2018-01-16       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.